VolitionRx Q Vet Cancer Test — VolitionRx presenting its Q Vet Cancer Test at the 2025 WVC Conference, a non-invasive epigenetic blood test detecting multiple cancers in dogs, aimed at early-stage diagnosis in general veterinary practices with ease of use and affordability making it highly accessible — demonstrates the multi-cancer screening innovation. The test's ability to detect multiple cancer types from a single blood draw, combined with its suitability for general practice workflows without requiring specialist interpretation, creating the screening infrastructure that could identify 2.51 million newly affected dogs annually in the United States before clinical signs manifest.

AI-assisted pathology reducing inter-reader variability — IDEXX Laboratories integrating machine learning components into its reference laboratory diagnostic workflows through the enhanced VetPath oncology pathology panel launched in January 2025, enabling more consistent classification of cytology samples flagged for oncological review — demonstrates the diagnostic quality improvement. AI reducing the variability between pathologists in high-volume panel processing, improving diagnostic accuracy in general practices that previously lacked access to board-certified veterinary pathologists, while creating the quality assurance layer that supports treatment decisions in non-specialty settings.

Do you think routine annual liquid biopsy screening for all dogs over age seven will become standard of care within the next decade, or will the cost sensitivity of pet owners, limited pet insurance coverage for screening diagnostics, and the psychological burden of incidental findings limit adoption to high-risk breeds and affluent pet owner segments?

FAQ

What AI and liquid biopsy diagnostics are available for veterinary cancer detection? IDEXX Cancer Dx: blood-based, early lymphoma detection, $15, launched January 2025, general practice integration; VolitionRx Q Vet Cancer Test: epigenetic, multi-cancer detection, non-invasive, presented WVC 2025; PetDx OncoK9: cell-free DNA, multi-cancer early detection, $400-500; ImpriMed AI Drug Response: live cell testing + AI prediction, 300+ oncologists, 250+ hospitals, 15,000+ tests; VetPath AI-enhanced pathology: cytology classification, IDEXX, launched January 2025; Antech Nu.Q Vet: nucleosome quantification, epigenetic; FidoCure genomic profiling: targeted therapy matching, $1,500-2,500; Traditional diagnostics: fine needle aspirate ($200-500), biopsy/histopathology ($300-800), flow cytometry ($400-800), imaging (X-ray $150-400, ultrasound $300-600, CT $1,500-3,000); Screening recommendations: annual for dogs >7 years, bi-annual for high-risk breeds (Golden Retrievers, Boxers, Bernese Mountain Dogs).